Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer Article Swipe
Related Concepts
Medicine
Baseline (sea)
Ovarian cancer
Oncology
Internal medicine
Overall survival
Cancer
Progression-free survival
Geology
Oceanography
Felicia Roncolato
,
Madeleine King
,
Rachel O’Connell
,
Yeh Chen Lee
,
Florence Joly
,
Felix Hilpert
,
Anne Lanceley
,
Yoshio Yoshida
,
Jane Bryce
,
Paul Donnellan
,
Amit M. Oza
,
Elisabeth Åvall‐Lundqvist
,
Jonathan S. Berek
,
Jonathan A. Ledermann
,
Dominique Berton-Rigaud
,
Jalid Sehouli
,
Marie‐Christine Kaminsky
,
Martin R. Stockler
,
Michael Friedländer
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.ygyno.2024.02.025
· OA: W4392180369
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.ygyno.2024.02.025
· OA: W4392180369
Pts with ROC reported high SB prior to starting palliative chemotherapy, similar among PRR-ROC and PPS-ROC≥3. High SB was strongly associated with early progression and death. SB should be actively managed and used to stratify patients in clinical trials. Clinical trials should measure and report symptom burden and the impact of treatment on symptom control.
Related Topics
Finding more related topics…